WVP
APTO

Worth Venture Partners’s Aptose Biosciences, Inc. APTO Stock Holding History

Worth Venture Partners’s Portfolio APTO Stock Details APTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-140
Closed -$131K – 111
2019
Q3 		$131K Buy
+140
New +$159K 0.07% 75

Other funds holding APTO

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
PAWC
P.A.W. Capital Greenwich, Connecticut $88.2M AUM 25.13% 1-Year Est. Return

Worth Venture Partners's APTO Position: Q4 2019 in Review

Worth Venture Partners sold out of Aptose Biosciences, Inc. (APTO) in Q4 2019, closing a stake of 140 shares — an estimated $131K sold.

Worth Venture Partners first reported a position in APTO in Q3 2019 and held it in 1 quarter. The position peaked at $131K in Q3 2019. 56 funds tracked by Wall St. Rank hold APTO as of Q4 2019.

  • Worth Venture Partners reported no remaining Aptose Biosciences, Inc. position as of Q4 2019 after selling out during the quarter.
  • Worth Venture Partners sold 140 Aptose Biosciences, Inc. shares in Q4 2019, an estimated $131K.
  • Worth Venture Partners first reported a position in Aptose Biosciences, Inc. in Q3 2019 and held it in 1 quarter.
  • Worth Venture Partners's Aptose Biosciences, Inc. position peaked at $131K in Q3 2019.
  • 56 funds tracked by Wall St. Rank held Aptose Biosciences, Inc. as of Q4 2019.

Based on Worth Venture Partners's 13F filing for Q4 2019, filed 14 Feb 2020.